Role of plasminogen activator-plasmin system in tumor angiogenesis

Cellular and Molecular Life Sciences

Volumn 60, Issue 3, 2003, Pages 463-473

  Rakic, J M ^a   Maillard, C ^b   Jost, M ^b   Bajou, K ^b   Masson, V ^b   Devy, L ^b   Lambert, V ^b   Foidart, J M ^b   Noel A ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Angiogenesis; Extracellular matrix; PAI l; Plasminogen; Proteinase inhibitor

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; CALRETICULIN; CYTOKINE; GELATINASE A; GROWTH FACTOR; IMMUNOGLOBULIN G; KININOGEN; MATRIGEL; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE INHIBITOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CELL MIGRATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; TUMOR; TUMOR GROWTH;

ANIMALS; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; SIGNAL TRANSDUCTION; VIRUSES;

EID: 0037362557     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180300039     Document Type: Review

References (130)

1. Carmeliet P. and Jain R. K. (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
2. Rafii S. (2000) Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest 105: 17-19
3. Yancopoulos G. D., Davis S., Gale N. W., Rudge J. S., Wiegand S. J. and Holash J. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248
4. Liekens S., De Clercq E. and Neyts J. (2001) Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61: 253-270
5. Hanahan D. and Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364
6. Benjamin L. E., Golijanin D., Itin A., Pode D. and Keshet E. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:159-165
7. Richard D. E., Berra E. and Pouyssegur J. (1999) Angiogenesis: how a tumor adapts to hypoxia. Biochem. Biophys. Res. Commun. 266:718-722
8. Folkman J. (1996) Tumor angiogenesis and tissue factor. Nat. Med. 2: 167-168
9. Dvorak H. F., Brown L. F., Detmar M. and Dvorak A. M. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146: 1029-1039
10. Eliceiri B. P. and Cheresh D. A. (1999) The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103: 1227-1230
11. Brooks P. C. (1996) Role of integrins in angiogenesis. Eur. J. Cancer 32A: 2423-2429
12. Scatena M. and Giachelli C. (2002) The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway: potential role in angiogenesis. Trends Cardiovasc. Med. 12: 83-88
13. Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G. et al. (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164
14. Reynolds L. E., Wyder L., Lively J. C., Taverna D., Robinson D., Huang X. et al. (2002) Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 8: 27-34
15. Cheresh D. A. and Stupack D. G. (2002) Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat. Med. 8: 193-194
16. Stromblad S., Fotedar A., Brickner H., Theesfeld C., Aguilar D. D., Friedlander M. et al. (2002) Loss of p53 compensates for alpha v-integrin function in retinal neovascularization. J. Biol. Chem. 277: 13371-13374
17. Noel A., Gilles C., Bajou K., Devy L., Kebers F., Lewalle J. M. et al. (1997) Emerging roles for proteinases in cancer. Invasion Metastasis 17: 221-239
18. Rifkin D. B., Mazzieri R., Munger J. S., Noguera I. and Sung J. (1999) Proteolytic control of growth factor availability. APMIS 107: 80-85
19. Egeblad M. and Werb Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. 2: 163-176
20. Twining S. S. (1994) Regulation of proteolytic activity in tissues. Crit Rev. Biochem. Mol. Biol. 29: 315-383
21. Carmeliet P., Kieckens L., Schoonjans L., Ream B., Nuffelen A. van, Prendergast G. et al. (1993) Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J. Clin. Invest. 92: 2746-2755
22. Carmeliet P., Stassen J. M., Schoonjans L., Ream B., Oord J. J. van den, De Mol M. et al. (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. Clin. Invest. 92: 2756-2760
23. Carmeliet P., Schoonjans L., Kieckens L., Ream B., Degen J., Bronson R. et al. (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424
24. Dewerchin M., Nuffelen A. V., Wallays G., Bouche A., Moons L., Carmeliet P. et al. (1996) Generation and characterization of urokinase receptor-deficient mice. J. Clin. Invest. 97: 870-878
25. Lijnen H. R., Okada K., Matsuo O., Collen D. and Dewerchin M. (1999) Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 93: 2274-2281
26. Ploplis V. A., Carmeliet P., Vazirzadeh S., Van V. I, Moons L. and Plow E. F. (1995) Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 92: 2585-2593
27. Ploplis V. A., Wilberding J., McLennan L., Liang Z., Cornelissen I., DeFord M. E. et al. (2000) A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice. Am. J. Pathol. 157: 703-708
28. Collen D. and Lijnen H. R. (1991) Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78: 3114-3124
29. Andreasen P. A., Kjoller L., Christensen L. and Duffy M. J. (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72: 1-22
30. Carmeliet P. and Collen D. (2000) Transgenic mouse models in angiogenesis and cardiovascular disease. J. Pathol. 190: 387-405
31. Blasi F. (1997) uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol. Today 18: 415-417
32. Lee S. L., Dickson R. B. and Lin C. Y. (2000) Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275: 36720-36725
33. Schmaier A. H. (2000) Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr. Opin. Hematol. 7: 261-265
34. Binnema D. J., Dooijewaard G. and Turion P. N. (1991) An analysis of the activators of single-chain urokinase-type plasminogen activator (scu-PA) in the dextran sulphate euglobulin fraction of normal plasma and of plasmas deficient in factor XII and prekallikrein. Thromb. Haemost. 65: 144-148
35. Hall S. W., Humphries J. E. and Gonias S. L. (1991) Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J. Biol. Chem. 266: 12329-12336
36. Plow E. F., Herren T., Redlitz A., Miles L. A. and Hoover-Plow J. L. (1995) The cell biology of the plasminogen system. FASEB J. 9: 939-945
37. Schmitt M., Wilhelm O., Reuning U., Kruger A. and Harbec N. et al. (2000) The urokinase plasminogen activator system as a novel target for turnout therapy. Fibrinolysis Proteolysis 14: 114-132
38. Blasi F. (1999) The urokinase receptor: a cell surface, regulated chemokine. APMIS 107: 96-101
39. Blasi F. (1999) Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb. Haemost. 82: 298-304
40. Chapman H. A. (1997) Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 9: 714-724
41. Xue W., Mizukami I., Tod R. F. III and Petty H. R. (1997) Urokinase-type plasminogen activator receptors associate with β1 and β3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 57: 1682-1689
42. Mazar A. P. (2001) The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 12: 387-400
43. Busso N., Masur S. K., Lazega D., Waxman S. and Ossowski L. (1994) Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J. Cell Biol. 126: 259-270
44. Wei Y., Yang X., Liu Q., Wilkins J. A. and Chapman H. A. (1999) A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell Biol. 144: 1285-1294
45. Hekman C. M. and Loskutoff D. J. (1985) Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem. 260: 11581-11587
46. Loskutoff D. J., Curriden S. A., Hu G. and Deng G. (1999) Regulation of cell adhesion by PAI-1. APMIS 107: 54-61
47. Salonen E. M., Vaheri A., Pollanen J., Stephens R., Andreasen P., Mayer M. et al. (1989) Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J. Biol. Chem. 264: 6339-6343
48. Wiman B., Almquist A., Sigurdardottir O. and Lindahl T (1988) Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett. 242: 125-128
49. Sugiura Y., Ma L., Sun B., Shimada H., Laug W. E., Seeger R. C. et al. (1999) The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res. 59: 1327-1336
50. Stefansson S. and Lawrence D. A. (1996) The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 383: 441-443
51. Kjoller L., Kanse S. M., Kirkegaard T., Rodenburg W., Ronne E., Goodman S. L. et al. (1997) Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 232: 420-429
52. Waltz D. A., Natkin L. R., Fujita R. M., Wei Y. and Chapman H. A. (1997) Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100: 58-67
53. Deng G., Curriden S. A., Wang S., Rosenberg S. and Loskutoff D. J. (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134: 1-9
54. Simpson A. J., Booth N. A., Moore N. R. and Bennett B. (1991) Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J. Clin. Pathol. 44: 139-143
55. Bacharach E., Itin A. and Keshet E. (1992) In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc. Natl. Acad. Sci. USA 89: 10686-10690
56. Pepper M. S., Vassalli J. D., Montesano R. and Orci L. (1987) Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol. 105: 2535-2541
57. Pepper M. S., Sappino A. P., Montesano R., Orcin L. and Vassalli J. D. (1992) Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J. Cell Physiol. 153: 129-139
58. Pepper M. S., Sappino A. P., Stocklin R., Montesano R., Orci L. and Vassalli J. D. (1993) Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol. 122: 673-684
59. Uchiyama T., Kurabayashi M., Ohyama Y., Utsugi T., Akuzawa N., Sato M. et al. (2000) Hypoxia induces transcription of the plasminogen activator inhibitor-1 gene through genistein-sensitive tyrosine kinase pathways in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20: 1155-1161
60. Bacharach E., Itin A. and Keshet E. (1998) Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: a mechanism for balancing pericellular proteolysis during angiogenesis. Blood 92: 939-945
61. Romer J., Bugge T. H., Pyke C., Lund L. R., Flick M. J., Degen J. L. et al. (1996) Plasminogen and wound healing. Nat. Med. 2: 725
62. Stephens R. W., Brunner N., Janicke F. and Schmitt M. (1998) The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res. Treat. 52: 99-111
63. Pedersen H., Brunner N., Francis D., Osterlind K., Ronne E., Hansen H. H. et al. (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54: 4671-4675
64. Naitoh H., Eguchi Y., Ueyama H., Kodama M. and Hattori T. (1995) Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1,2 and plasminogen in colon cancer. Jpn. J. Cancer Res. 86: 48-56
65. Harvey S. R., Sait S. N., Xu Y., Bailey J. L., Penetrante R. M. and Markus G. (1999) Demonstration of urokinase expression in cancer cells of colon adenocarcinomas by immunohistochemistry and in situ hybridization. Am. J. Pathol. 155: 1115-1120
66. Nielsen B. S., Sehested M., Timshel M., Pyke C. and Dano K. (1996) Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab. Invest. 74: 168-177
67. Umeda T., Eguchi Y., Okino K., Kodama M. and Hattori T. (1997) Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J. Pathol. 183: 388-397
68. Nielsen B. S., Sehested M., Duun S., Rank F., Timshel S., Rygaard J. et al. (2001) Urokinase plasminogen activator is localized in stromal cells in ductal breast cancer. Lab. Invest. 81: 1485-1501
69. Dublin E., Hanby A., Patel N. K., Liebman R. and Barnes D. (2000) Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Am. J. Pathol. 157: 1219-1227
70. Min HY., Doyle L. V., Vitt C. R., Zandonella C. L., Stratton-Thomas J. R., Shuman M. A. et al. (1996) Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res. 56: 2428-2433
71. Li H., Lu H., Griscelli F., Opolon P., Sun L. Q., Ragot T. et al. (1998) Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. 5: 1105-1113
72. Evans C. P., Elfman F., Parangi S., Conn M., Cunha G. and Shuman M. A. (1997) Inhibition of prostate cancer neovascularization and growth by urokinase-plasminogen activator receptor blockade. Cancer Res. 57: 3594-3599
73. Pepper M. S. (2001) Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21: 1104-1117
74. Montesano R., Pepper M. S., Mohle-Steinlein U., Risau W., Wagner E. F. and Orci L. (1990) Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62: 435-445
75. Sabapathy K. T., Pepper M. S., Kiefer F., Möhle-Steinlein U., Tacchini-Cottier F., Fetka I. et al. (1997) Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system. J. Cell Biol. 137: 953-963
76. Lijnen H. R., Wagner E. F. and Collen D. (1997) Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes. Thromb. Haemost. 77: 362-367
77. O'Reilly M. S., Holmgren L., Shing Y., Chen C., Rosenthal R A, Moses M. et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328
78. O'Reilly M. S., Boehm T., Shing Y., Fuka N., Vasios G., Lane W. S. et al. (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285
79. Stack M. S., Gately S., Bafetti L. M., Enghild J. and Soff G. A. (1999) Angiostatin inhibitits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem. J. 340: 77-84
80. Gately S., Twardowski P., Stack M. S., Cundiff D. L., Grella D., Castellino F. J. et al. (1997) The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA 94: 10868-10872
81. Ramchandran R., Dhanabal M., Volk R., Waterman M. J., Segal M., Lu H. et al. (1999) Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys. Res. Commun. 255: 735-739
82. Colorado P. C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K. et al. (2000) Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60: 2520-2526
83. Kamphaus G. D., Colorado P. C., Panka D. J., Hopfer H., Ram-chandran R., Torre A. et al. (2000) Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275: 1209-1215
84. Maeshima Y., Colorado P. C. and Kalluri R. (2000) Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J. Biol. Chem. 275: 23745-23750
85. Maeshima Y., Manfredi M., Reimer C., Holthaus K. A., Hopfer H., Chandamuri B. R. et al. (2001) Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 276: 15240-15248
86. Maeshima Y., Yerramalla U. L., Dhanabal M., Holthaus K. A., Barbashov S., Kharbanda S. et al. (2001 ) Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J. Biol. Chem. 276: 31959-31968
87. O'Reilly M. S., Pirie-Shepherd S., Lane W. S. and Folkman J. (1999) Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285: 1926-1928
88. Pike S. E., Yao L., Jones K. D., Cherney B., Appella E., Sakaguchi K. et al. (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med. 188: 2349-2356
89. Colman R. W., Jameson B. A., Lin Y., Johnson D. and Mousa S. A. (2000) Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 95: 543-550
90. Tsuojiya H., Katsuo E., Sunayama C., Tomita K., Ueda Y. and Binder B. R. (1995) The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice. Gen. Diagn. Pathol. 141: 41-48
91. Bajou K., Noel A., Gerard R. D., Masson V., Brunner N., Holst-Hansen C. et al. (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med 4: 923-928
92. Bajou K., Masson V., Gerard R. D., Schmitt P., Albert V., Praus M. et al. (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J. Cell Biol. 152: 777-784
93. Gutierrez L. S., Schulman A., Brito-Robinson T., Noria F., Ploplis V. A. and Castellino F. J. (2000) Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 60: 5839-5847
94. Lambert V., Munaut C., Noel A., Frankenne F., Bajou K., Gerard R. et al. (2001) Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 15: 1021-1027
95. McMahon G. A., Petitclerc E., Stefansson S., Smith E., Wong M. K., Westrick R. J. et al. (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276: 33964-33968
96. Devy L., Blacher S., Grignet-Debrus C., Bajou K., Masson V., Gerard R. D. et al. (2002) The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 16: 147-154
97. Pepper M. S. and Montesano R. (1990) Proteolytic balance and capillary morphogenesis. Cell Differ. Dev. 32: 319-327
98. Stefansson S., Petitclerc E., Wong M. K., McMahon G. A., Brooks P. C. and Lawrence D. A. (2001) Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J. Biol. Chem. 276: 8135-8141
99. Reuning U., Magdolen V., Wilhelm O., Fischer K., Lutz V., Graeff H. et al. (1998) Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol. 13: 893-906
100. Muehlenweg B., Sperl S., Magdolen V., Schmitt M. and Harbeck N. (2001) Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert. Opin. Biol. Ther. 1: 683-691
101. Janicke F., Prechtl A., Thomssen C., Harbeck N., Meisner C., Untch M. et al. (2001) Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 93: 913-920
102. Cousssens L. M., Fingleton B. and Matrisian L. M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392
103. Wilhelm O., Schmitt M., Hohl S., Senekowitsch R. and Graeff H. (1995) Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin. Exp. Metastasis 13: 296-302
104. Morrissey D., O'Connell J., Lynch D., O'Sullivan G. C., Shanahan F. and Collins J. K. (1999) Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor. Clin. Exp. Metastasis 17: 77-85
105. Moran P. M., Chintala S. K., Mohanam S., Gladson C. L., Kim E. S., Gokaslan Z. L. et al. (1999) Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth. Cancer Res. 59: 3369-3373
106. Aguirre Ghiso J. A., Kovalski K. and Ossowski L. (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J. Cell Biol. 147: 89-104
107. Swiercz R., Skrzypczak-Jankun E., Merrell M. M., Selman S. H. and Jankun J. (1999) Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol. Rep. 6: 523-526
108. Guo Y., Higazi A. A., Arakelian A., Sachais B. S., Cines D., Goldfarb R. H. et al. (2000) A peptide derived from the non-receptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 14: 1400-1410
109. Mishima K., Mazar A. P., Gown A., Skelly M., Ji X. D., Wang X. D. et al. (2000) A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc. Natl. Acad. Sci. USA 97: 8484-8489
110. Kobayashi H., Gotoh J., Fujie M., Shinohara H., Moniwa N. and Terao T. (1994) Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor-like domain of urokinase in the experimental and spontaneous metastasis model. Int. J. Cancer 57: 727-733
111. Burgle M., Koppitz M., Riemer C., Kessler H., Konig B., Weidle U. H. et al. (1997) Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol. Chem. 378: 231-237
112. Goodson R. J., Doyle M. V., Kaufman S. E. and Rosenberg S. (1994) High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA 91: 7129-7133
113. Fong S., Doyle M. V., Goodson R. J., Drummond R. J., Stratton J. R., McGuire L. et al. (2002) Random peptide bacteriophage display as a probe for urokinase receptor ligands. Biol. Chem. 383: 149-158
114. Luther T., Magdolen V., Albrecht S., Kasper M., Riemer C., Kessler H. et al. (1997) Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am. J. Pathol. 150: 1231-1244
115. Behrendt N., Ronne E. and Dano K. (1993) Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J. Biol. Chem. 268: 5985-5989
116. Botta M., Manetti F. and Corelli F. (2000) Fibroblast growth factors and their inhibitors. Curr. Pharm. Des. 6: 1897-1924
117. Zugmaier G., Favoni R., Jaeger R., Rosen N. and Knabbe C. (1999) Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors. Ann. N. Y. Acad. Sci. 886: 243-248
118. Wei Y., Lukashev M., Simon D. I., Bodary S. C., Rosenberg S., Doyle M. V. et al. (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555
119. Simon D. I., Wei Y., Zhang L., Rao N. K., Xu H., Chen Z. et al. (2000) Identification of a urokinase receptor-integrin interaction site: promiscuous regulator of integrin function. J. Biol. Chem. 275: 10228-10234
120. Ma D., Gerard R. D., Li X. Y., Alizadeh H. and Niederkorn J. Y. (1997) Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 90: 2738-2746
121. Praus M., Wauterickx K., Collen D. and Gerard R. D. (1999) Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther. 6: 236
122. Lentschener C., Li H., Franco D., Mercier F. J., Lu H., Soria J. et al. (1999) Intraoperatively administered aprotinin increases one year survival after elective liver resection for colorectal metastasis. Proteolysis Fibrinolysis 13: 39-45
123. Liu S., Bugge T. H. and Leppla S. H. (2001) Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J. Biol. Chem. 276: 17976-17984
124. Chakravarty P. K., Carl P. L., Weber M. J. and Katzenellenbogen J. A. (1983) Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J. Med. Chem. 26: 638-644
125. Khan S. R. and Denmeade S. R. (2000) In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate 45: 80-83
126. DiPaola R. S., Rinehart J., Nemunaitis J., Ebbinghaus S., Rubin E., Capanna T. et al. (2002) Characterization of a novel prostate-specific antigen-activated peptide- doxorubicin conjugate in patients with prostate cancer. J. Clin. Oncol. 20: 1874-1879
127. Griffioen A. W. and Molema G. (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52: 237-268
128. Van Trappen P. O. and Pepper M. S. (2002) Lymphatic dissemination of tumour cells and the formation of micrometasrases. Lancet Oncol. 3: 44-52
129. Pepper M. S., Mandriota S. J., Jeltsch M., Kumar V. and Alitalo K. (1998) Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J. Cell Physiol. 177: 439-452
130. Leak L. V., Saunders M., Day A. A. and Jones M. (2000) Stimulation of plasminogen activator and inhibitor in the lymphatic endothelium. Microvasc. Res. 60: 201-211